Key stats
About LEGAL & GENERAL UCITS ETF PLC PHARMA BREAKTHROUGH UCITS ETF VCIC ACC
Home page
Inception date
Jan 23, 2018
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
LGIM Managers (Europe) Ltd.
ISIN
IE00BF0H7608
The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.88%
Health Technology94.78%
Process Industries5.10%
Bonds, Cash & Other0.12%
Cash0.12%
Stock breakdown by region
North America55.47%
Europe24.48%
Asia20.05%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BIOT invests in stocks. The fund's major sectors are Health Technology, with 94.78% stocks, and Process Industries, with 5.10% of the basket. The assets are mostly located in the North America region.
BIOT top holdings are InnoCare Pharma Ltd. and BioCryst Pharmaceuticals, Inc., occupying 3.69% and 3.64% of the portfolio correspondingly.
BIOT assets under management is 15.33 M EUR. It's fallen 17.75% over the last month.
BIOT fund flows account for −1.57 M EUR (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, BIOT doesn't pay dividends to its holders.
BIOT shares are issued by Legal & General Group Plc under the brand L&G. The ETF was launched on Jan 23, 2018, and its management style is Passive.
BIOT expense ratio is 0.49% meaning you'd have to pay 0.49% of your investment to help manage the fund.
BIOT follows the Solactive Pharma Breakthrough Value Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BIOT invests in stocks.
BIOT price has risen by 0.80% over the last month, and its yearly performance shows a 3.05% increase. See more dynamics on BIOT price chart.
NAV returns, another gauge of an ETF dynamics, have risen by −1.27% over the last month, have fallen by −1.27% over the last month, showed a −9.65% decrease in three-month performance and has increased by 3.55% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by −1.27% over the last month, have fallen by −1.27% over the last month, showed a −9.65% decrease in three-month performance and has increased by 3.55% in a year.
BIOT trades at a premium (0.17%) meaning the ETF is trading at a higher price than the calculated NAV.